The Office of Orphan Product Development in the Food and Drug Administration has awarded more than $1 million to the University of Arizona’s Valley Fever Center for Excellence. The grant will help fund Phase One and Phase Two clinical trials for nikkomycin Z, a promising investigational treatment for valley fever.
